Helius Medical Technologies, Inc. (HSDT)
NASDAQ: HSDT · Real-Time Price · USD
0.4459
+0.0449 (11.20%)
Apr 1, 2025, 10:24 AM EDT - Market open
HSDT Revenue
In the year 2024, Helius Medical Technologies had annual revenue of $520.00K, down -19.25%. Helius Medical Technologies had revenue of $152.00K in the quarter ending December 31, 2024, with 13.43% growth.
Revenue (ttm)
$520.00K
Revenue Growth
-19.25%
P/S Ratio
2.09
Revenue / Employee
$23,636
Employees
22
Market Cap
2.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 520.00K | -124.00K | -19.25% |
| Dec 31, 2023 | 644.00K | -143.00K | -18.17% |
| Dec 31, 2022 | 787.00K | 265.00K | 50.77% |
| Dec 31, 2021 | 522.00K | -139.00K | -21.03% |
| Dec 31, 2020 | 661.00K | -835.00K | -55.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
HSDT News
- 19 days ago - Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary - GlobeNewsWire
- 21 days ago - Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire
- 2 months ago - Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study - GlobeNewsWire
- 2 months ago - Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market - GlobeNewsWire
- 3 months ago - Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System - GlobeNewsWire
- 4 months ago - Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire
- 6 months ago - Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece - GlobeNewsWire
- 8 months ago - Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire